Rocket Pharmaceuticals Bolsa (NASDAQ: RCKT)

Últimas noticias sobre Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Citigroup analyst Drew Foster maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $750 to $900.

Price Target

Analyst Ratings

HUBS

Citigroup Maintains Buy on HubSpot, Raises Price Target to $900

The OASIS+ vehicle has an estimated total spend of $60 billion over a maximum of 10 years.

Contracts

ASGN

ASGN Says Its Brand ECS Named As Prime Contractor On $60B OASIS+ IDIQ Contract

THRD

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

LASE

Laser Photonics Secures Repeat Order From Bruce Power, Advancing Eco-Friendly Laser Cleaning In Nuclear Plants

Morgan Stanley analyst Dara Mohsenian maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Underweight and lowers the price target from $35 to $32.

Morgan Stanley Maintains Underweight on Edgewell Personal Care, Lowers Price Target to $32

Laser Photonics Receives Order For Second And Third CleanTech 500-CTHD Laser Cleaning System From Sargent & Lundy For Use By Bruce Power In Ontario, Canada

Biotech

Earnings

Guidance

Health Care

General

RPRX

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $200 to $217.

EXPE

Citigroup Maintains Neutral on Expedia Group, Raises Price Target to $217

SPGI

S&P Global Authorized Repurchase Of Shares Totaling Up To $4.3B; Expects To Launch An Initial $650M Accelerated Share Repurchase In Coming Weeks

SHOP: -11% &#x7C; <a href="https://www.benzinga.com//node/43619343">Shopify shares are trading lower following Q4 financial results.</a>
&nbsp;
IINN: 33% &#x7C; <a href="https://www.benzinga.com//node/43618385">EXCLUSIVE: Inspira Technologies Tells Benzinga 'Initial ex-vivo testing demonstrates significant bacterial reduction potential for innovative IV dressing technology aimed at preventing bloodstream infections'</a>
&nbsp;
LIPO: 81% &#x7C; <a href="https://www.benzinga.com//node/43617270">Lipella Pharmaceuticals Shares Phase 2a Results For LP-310 In The Treatment Of Oral Lichen Planus, Showing Favorable Safety Profile And Tolerability Of Twice-Daily Oral Rinse</a>

Movers

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

LIPO

SHOP

Market-Moving News for February 11th

Needham analyst Quinn Bolton reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $70 price target.

Reiteration

LSCC

Needham Reiterates Buy on Lattice Semiconductor, Maintains $70 Price Target

Morgan Stanley analyst Toni Kaplan maintains Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) with a Underweight and lowers the price target from $102 to $100.

BFAM

Morgan Stanley Maintains Underweight on Bright Horizons Family, Lowers Price Target to $100

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 million by 12.50 percent. This is a 0.34 percent decrease over sales of $596.00 million the same period last year.

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

S&P Global Sees FY25 Revenue Growth Of 5%-7%, And Adjusted Diluted EPS Of $17.00-$17.25 Vs. $16.92 Estimate

FLXS

GigaCloud Technology Says Purple Innovation, Flexsteel Industries' Brand And Other Furniture Suppliers Has Joined Its GigaCloud Marketplace

Additionally, Anterix has launched a new industry engagement initiative to address and shorten the time to realization of value for Anterix and its customers to allow them to more quickly deploy 900 MHz private wireless broadband networks.&nbsp;

ATEX

Anterix Engages Morgan Stanley To Begin Strategic Review Process After Receiving Inbound Interest In The Company

The recent spotlight on DeepSeek&#8217;s owner, <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">High-Flyer</a> has renewed interest in quantitative hedge funds. These are pooled funds that employ sophisticated mathematical and statistical models to identify and exploit market inefficiencies. Unlike traditional hedge funds that rely on fundamental analysis, quantitative hedge funds focus on statistical patterns and data-driven strategies to generate returns.
<h3 class="wp-block-heading">What Are Hedge Funds?</h3>
Hedge funds, in general, are private investment partnerships that cater to high-net-worth individuals and institutional investors. They are known for their flexible investment strategies and the potential for higher returns which is accompanied by higher risk. Retail investors cannot invest in hedge funds because of the higher amount of risk involved,
Quantitative hedge funds, a subset of this broader category, rely heavily on data analysis and algorithmic trading.
<h3 class="wp-block-heading">Quantitative Hedge Funds: A Deep Dive</h3>
Quantitative hedge funds use complex algorithms to sift through vast amounts of data, including historical price data, economic indicators, and news sentiment, to identify patterns and predict future price movements. These strategies can range from high-frequency trading, where positions are held for fractions of a second, to more long-term, statistically-driven investments.
While the specifics of each fund&#8217;s algorithms are proprietary, several common quantitative strategies exist:
<ul>
<li>Statistical Arbitrage: This strategy exploits temporary price differences between related assets, buying the undervalued asset and selling the overvalued one, profiting from price convergence.</li>
</ul>
<ul>
<li>Pairs Trading: This strategy targets two assets that historically move together, betting on the restoration of their correlation by going long on the underperforming asset and short on the outperforming one.</li>
</ul>
<ul>
<li>Trend Following: This strategy rides established market trends, using algorithms to profit from rising or falling prices.</li>
</ul>
<ul>
<li>Market Neutral: This strategy generates returns regardless of market movements by using algorithms to identify overvalued and undervalued securities, going long on the former and short on the latter, with minimal net market exposure. Leverage is often used to amplify returns and risks.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43614897/auto-slowdown-hits-on-semiconductor-in-q4-q1-outlook-also-dim-ceo-warns-of-persisting-volatility-due-to-the-geopolitical-uncertainty">Auto Slowdown Hits ON Semiconductor In Q4 — Q1 Outlook Also Dim: CEO Warns of &#8216;Persisting Volatility Due To The Geopolitical Uncertainty&#8217;</a>
Why It Matters: Mathematicians, statisticians, and programmers develop and refine their algorithms which are used to employ quantitative strategies. The development of these strategies is heavily reliant on vast amounts of data and sophisticated computing power because processing and analyzing data is crucial for success in this field.
The reliance on algorithms means that unforeseen events or market shocks can trigger rapid and substantial losses. The use of leverage can amplify both gains and losses.
This was evident in the case of High-Flyer too, which lost a third of its investors' money in 2022 amid the volatility in Chinese markets. The fund along with its majority stakeholder &nbsp;Liang Wenfeng <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">apologized</a> to its investors profusely via its official WeChat account after losing their money.
It was after this incident that the company exclusively committed to developing AI technology for the benefit of humanity, forming a new independent research group dedicated to exploring the potential of artificial general intelligence. This restructuring led to the <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">creation</a> of DeepSeek in 2023.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively ended higher on Monday. SPY rose 0.68% to $604.85, and QQQ advanced 1.21% to $529.25, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data. In premarket on Tuesday, SPY was down 0.21% and QQQ fell 0.29%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">DeepSeek&#8217;s Hedge Fund Owner Had Multiple Top Projects Before Creating The Firm That Fueled $1 Trillion Market Cap Erosion Of AI Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Tech

ETFs

As DeepSeek's Owner 'High-Flyer' Comes To Fore, Let's Understand What Is A Quantitative Hedge Fund And How Does It Work

Citigroup analyst Andrew Kaplowitz maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and raises the price target from $345 to $350.

Citigroup Maintains Buy on Rockwell Automation, Raises Price Target to $350

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $190 price target.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target

Citigroup analyst Paul Lejuez maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $98 to $120.

Citigroup Maintains Buy on Walmart, Raises Price Target to $120

Jefferies initiated coverage of Rocket Pharmaceuticals (RCKT) with a Buy rating and $29 price target The company has five potentially best- and fir...

Rocket Pharmaceuticals initiated with a Buy at Jefferies

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) on December 20 and set a price ...

Evercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

Yun Zhong, an analyst from Wedbush, has initiated a new Buy rating on Rocket Pharmaceuticals (RCKT). Yun Zhong has given his Buy rating due to a co...

Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating

Wedbush analyst Yun Zhong initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target Published first on The...

Rocket Pharmaceuticals initiated with an Outperform at Wedbush

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 "should be an ...

Wedbush starts Rocket Pharmaceuticals with Outperform into 'inflection year'

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The associated price target remai...

Buy Recommendation for Rocket Pharmaceuticals: Promising Potential of RP-L301 in Severe PKD Cases

JPMorgan analyst Eric Joseph lowered the firm's price target on Rocket Pharmaceuticals (RCKT) to $48 from $49 and keeps an Overweight rating on the...

Rocket Pharmaceuticals price target lowered to $48 from $49 at JPMorgan

AMTM

ARQT

ARTV

CDTX

CTOR

CTXR

EYEN

HSAI

KULR

MIST

MRNS

MSTR

NAMS

NUVL

NVDA

PGEN

RHHBY

RHHVF

SEAT

SGMO

TLRY

TTWO

VCSA

VSTM

WKSP

Press Releases

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Comments

Rocket Pharmaceuticals

Noticias

Últimas noticias sobre Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL